Cargando…

Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis

Detalles Bibliográficos
Autores principales:	Chan, Wah Loong, Chandra Kumar, C. Vikneshwaran, Chan, Wah Kheong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598320/ https://www.ncbi.nlm.nih.gov/pubmed/37886205 http://dx.doi.org/10.21037/hbsn-23-346

Ejemplares similares

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
por: Newsome, Philip N, et al.
Publicado: (2020)

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
por: Chandra Kumar, C. Vikneshwaran, et al.
Publicado: (2022)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
por: Lee, Jae Seung, et al.
Publicado: (2022)

Limited applicability of cathepsin D for the diagnosis and monitoring of non‐alcoholic steatohepatitis
por: Kamarajah, Sivesh K, et al.
Publicado: (2019)

Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers
por: Chan, Wah-Kheong, et al.
Publicado: (2014)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Chuah, Kee-Huat, et al.
Publicado: (2023)

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
por: Kawamura, Yusuke, et al.
Publicado: (2015)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

Comparison between obese and non-obese nonalcoholic fatty liver disease
por: Chan, Wah-Kheong
Publicado: (2023)

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
por: Ng, Ying Zhuang, et al.
Publicado: (2021)

Epidemiology of non‐alcoholic fatty liver disease‐related hepatocellular carcinoma and its implications
por: Wong, Sui‐Weng, et al.
Publicado: (2018)

Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease
por: Wong, Yu Jun, et al.
Publicado: (2023)

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
por: Ting, Yi-Wen, et al.
Publicado: (2021)

Use of simple scoring systems for a public health approach in the management of non‐alcoholic fatty liver disease patients
por: Zain, Shamsul Mohd, et al.
Publicado: (2020)

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
por: Sanyal, Arun J., et al.
Publicado: (2023)

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis
por: Pistorio, Valeria, et al.
Publicado: (2022)

FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
por: Zelenika, Marko, et al.
Publicado: (2021)

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
por: McPherson, Stuart, et al.
Publicado: (2017)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Amernia, Behnaz, et al.
Publicado: (2021)

Nitro-oleic acid as a new drug candidate for non-alcoholic steatohepatitis
por: Yang, Rui-Xu, et al.
Publicado: (2019)

Anti‐fibrotic activity of Euglena gracilis and paramylon in a mouse model of non‐alcoholic steatohepatitis
por: Nakashima, Ayaka, et al.
Publicado: (2018)

Association between non‐alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community
por: Tan, Eugene Choon‐Li, et al.
Publicado: (2018)

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
por: Wai-Sun Wong, Vincent, et al.
Publicado: (2023)

Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease
por: Lai, Lee-Lee, et al.
Publicado: (2017)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

A fast and accurate mouse model for inducing non-alcoholic steatohepatitis
por: Rahimi, Shahrzad, et al.
Publicado: (2022)

Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations
por: Heinrichs, Daniel, et al.
Publicado: (2021)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
por: Zhang, Huai, et al.
Publicado: (2023)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Correlation between Transient Elastography (Fibroscan(®)) and Ultrasonographic and Computed Tomographic Grading in Pediatric Nonalcoholic Steatohepatitis
por: Lee, Ji Eun, et al.
Publicado: (2022)

Integrating stress signals—XBP1 as a novel mediator of intercellular crosstalk in non-alcoholic steatohepatitis
por: Yu, Junjie, et al.
Publicado: (2022)

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2018)

A scoring system for the diagnosis of non-alcoholic steatohepatitis from liver biopsy
por: Lee, Kyoungbun, et al.
Publicado: (2020)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Evaluation of Patient Satisfaction of an Outpatient Colonoscopy Service in an Asian Tertiary Care Hospital
por: Chan, Wah-Kheong, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_udv6o70icrsa3rr9hb1d1lqnmp